Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Sen. VP Protein Platforms | October 26, 2017 | October 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date October 26, 2017 · Filed October 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,949 |
Reported balance
After 2017-10-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-26 · Grant · Acquired 1,949 · Balance 1,949 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,500 F4: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. F5: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,111 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 2,111 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 10,742 |
Reported balance
After 2017-10-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-26 · Grant · Acquired 10,742 · Balance 10,742 F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 14,323 |
Reported balance
After 2017-10-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-26 · Grant · Acquired 14,323 · Balance 14,323 F3: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18 | Direct | 13,028 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 13,028 F6: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18 | Direct | 17,371 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 17,371 F10: Vests 4,343 shares on each 8/18/2017, 8/18/2018 and 8/18/2019 and 4,342 shares on 8/18/2020 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.32 · Expires 2021-07-31 | Direct | 16,667 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 16,667 F11: Fully exercisable |
| Common StockSEC Table I · non-derivative | Direct | 1,667 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,667 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $108.49 · Expires 2022-08-07 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 12,500 F7: 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $108.49 · Expires 2022-08-07 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 9,375 F5: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.32 · Expires 2021-07-31 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 10,000 F8: 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.25 · Expires 2021-11-30 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-10-26 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 5,000 F9: 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F3: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.
F4: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock.
F5: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F6: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
F8: 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
F9: 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
F10: Vests 4,343 shares on each 8/18/2017, 8/18/2018 and 8/18/2019 and 4,342 shares on 8/18/2020
F11: Fully exercisable
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 14,323 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 4 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,323 Underlying: Common Stock · 14,323 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 10,742 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 3 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,742 Underlying: Common Stock · 10,742 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 2 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 Underlying: Common Stock · 1,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 5 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. F4 · derivative.exercise_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 1,667 performance RSUs. The remainder of the performance RSUs were foreited. F4 · derivative.expiration_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 1,667 performance RSUs. The remainder of the performance RSUs were foreited. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $93.32 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 3 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 33,333 shares Expires 2021-07-31 F2 · derivative.exercise_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 16,667 performance options. The remainder of the performance options were forfeited. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · nonDerivative · entry 1 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 11 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,111 Underlying: Common Stock · 2,111 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 13,028 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 10 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,028 Underlying: Common Stock · 13,028 shares Expires 2023-08-18 F9 · derivative.exercise_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 17,371 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 9 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,371 Underlying: Common Stock · 17,371 shares Expires 2023-08-18 F8 · derivative.exercise_date: Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.